UA129300C2 - Тверді форми n-трет-бутил-4[[2-(5-хлор-2-гідроксифеніл)ацетил]аміно]піридин-2-карбоксаміду - Google Patents
Тверді форми n-трет-бутил-4[[2-(5-хлор-2-гідроксифеніл)ацетил]аміно]піридин-2-карбоксаміду Download PDFInfo
- Publication number
- UA129300C2 UA129300C2 UAA202200857A UAA202200857A UA129300C2 UA 129300 C2 UA129300 C2 UA 129300C2 UA A202200857 A UAA202200857 A UA A202200857A UA A202200857 A UAA202200857 A UA A202200857A UA 129300 C2 UA129300 C2 UA 129300C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- zhe
- polymorph
- shche
- degrees
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910664.0A GB201910664D0 (en) | 2019-07-25 | 2019-07-25 | Novel forms of compound |
| PCT/GB2020/051779 WO2021014167A1 (en) | 2019-07-25 | 2020-07-24 | Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA129300C2 true UA129300C2 (uk) | 2025-03-12 |
Family
ID=67990591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202200857A UA129300C2 (uk) | 2019-07-25 | 2020-07-24 | Тверді форми n-трет-бутил-4[[2-(5-хлор-2-гідроксифеніл)ацетил]аміно]піридин-2-карбоксаміду |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12281077B2 (https=) |
| EP (1) | EP4003960A1 (https=) |
| JP (1) | JP7627683B2 (https=) |
| KR (1) | KR20220087430A (https=) |
| CN (1) | CN114585607B (https=) |
| AU (1) | AU2020318943A1 (https=) |
| BR (1) | BR112022001276A2 (https=) |
| CA (1) | CA3145285A1 (https=) |
| CL (1) | CL2022000187A1 (https=) |
| CO (1) | CO2022002046A2 (https=) |
| CR (2) | CR20220079A (https=) |
| GB (1) | GB201910664D0 (https=) |
| IL (1) | IL290071B1 (https=) |
| MX (1) | MX2022000891A (https=) |
| MY (1) | MY207877A (https=) |
| PE (1) | PE20221407A1 (https=) |
| PH (1) | PH12022550193A1 (https=) |
| UA (1) | UA129300C2 (https=) |
| WO (1) | WO2021014167A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176767A1 (en) * | 2003-10-30 | 2005-08-11 | Laval Chan Chun Kong | Pyridine carboxamide and methods for inhibiting HIV integrase |
| CA2658362A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| WO2016042114A1 (en) * | 2014-09-19 | 2016-03-24 | F. Hoffmann-La Roche Ag | Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis |
| US11358947B2 (en) | 2017-04-17 | 2022-06-14 | The Regents Of The University Of California | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
-
2019
- 2019-07-25 GB GBGB1910664.0A patent/GB201910664D0/en not_active Ceased
-
2020
- 2020-07-24 MY MYPI2022000419A patent/MY207877A/en unknown
- 2020-07-24 WO PCT/GB2020/051779 patent/WO2021014167A1/en not_active Ceased
- 2020-07-24 CN CN202080053826.8A patent/CN114585607B/zh active Active
- 2020-07-24 PE PE2022000136A patent/PE20221407A1/es unknown
- 2020-07-24 PH PH1/2022/550193A patent/PH12022550193A1/en unknown
- 2020-07-24 JP JP2022505329A patent/JP7627683B2/ja active Active
- 2020-07-24 AU AU2020318943A patent/AU2020318943A1/en active Pending
- 2020-07-24 KR KR1020227006247A patent/KR20220087430A/ko active Pending
- 2020-07-24 EP EP20751235.1A patent/EP4003960A1/en active Pending
- 2020-07-24 IL IL290071A patent/IL290071B1/en unknown
- 2020-07-24 MX MX2022000891A patent/MX2022000891A/es unknown
- 2020-07-24 CA CA3145285A patent/CA3145285A1/en active Pending
- 2020-07-24 CR CR20220079A patent/CR20220079A/es unknown
- 2020-07-24 UA UAA202200857A patent/UA129300C2/uk unknown
- 2020-07-24 CR CR20250316A patent/CR20250316A/es unknown
- 2020-07-24 BR BR112022001276A patent/BR112022001276A2/pt unknown
-
2022
- 2022-01-24 CL CL2022000187A patent/CL2022000187A1/es unknown
- 2022-01-24 US US17/582,539 patent/US12281077B2/en active Active
- 2022-02-25 CO CONC2022/0002046A patent/CO2022002046A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3145285A1 (en) | 2021-01-28 |
| GB201910664D0 (en) | 2019-09-11 |
| IL290071B1 (en) | 2026-02-01 |
| AU2020318943A1 (en) | 2022-03-17 |
| JP2022542918A (ja) | 2022-10-07 |
| BR112022001276A2 (pt) | 2022-03-22 |
| JP7627683B2 (ja) | 2025-02-06 |
| KR20220087430A (ko) | 2022-06-24 |
| PH12022550193A1 (en) | 2023-01-09 |
| MX2022000891A (es) | 2022-05-26 |
| EP4003960A1 (en) | 2022-06-01 |
| US20220220074A1 (en) | 2022-07-14 |
| US12281077B2 (en) | 2025-04-22 |
| CN114585607B (zh) | 2025-11-14 |
| CL2022000187A1 (es) | 2022-10-07 |
| CO2022002046A2 (es) | 2022-06-10 |
| CR20220079A (es) | 2022-06-28 |
| CR20250316A (es) | 2025-08-27 |
| CN114585607A (zh) | 2022-06-03 |
| IL290071A (en) | 2022-03-01 |
| WO2021014167A1 (en) | 2021-01-28 |
| PE20221407A1 (es) | 2022-09-20 |
| MY207877A (en) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111683926B (zh) | 化合物 | |
| JP2022137223A (ja) | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス | |
| CN101918418A (zh) | 替诺福韦地索普西的固体形式 | |
| US20230312469A1 (en) | Crystalline salt forms of mesembrine | |
| EP2440560A1 (en) | The succinate of tenofovir disoproxil | |
| CN111094235A (zh) | 无定形形式的维兰特罗三苯乙酸盐及其制备方法 | |
| JP7448541B2 (ja) | 選択的エストロゲン受容体分解剤の新規な塩 | |
| US20040063782A1 (en) | Bicalutamide forms | |
| JP2024524701A (ja) | ２－（３－（４－（１ｈ－インダゾール－５－イルアミノ）キナゾリン－２－イル）フェノキシ）－ｎ－イソプロピルアセトアミドメタンスルホン酸塩の固体形態 | |
| UA129300C2 (uk) | Тверді форми n-трет-бутил-4[[2-(5-хлор-2-гідроксифеніл)ацетил]аміно]піридин-2-карбоксаміду | |
| US20220098164A1 (en) | Modulators of tmem16a for treating respiratory disease | |
| CN101910118A (zh) | 磷酸奥司他韦的多晶型 | |
| TW202545917A (zh) | Ｎ－［（１ｓ，２ｅ）－１－環丙基－３－（甲磺醯基）丙－２－烯－１－基］－２－（１，１－二氟乙基）－４－苯氧基嘧啶－５－甲醯胺的新固體形式 | |
| RU2843949C2 (ru) | Твердые формы n-трет-бутил-4[[2-(5-хлор-2-гидроксифенил)ацетил]амино]пиридин-2-карбоксамида | |
| CA3145120A1 (en) | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions | |
| WO2021014168A1 (en) | Solid forms of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide | |
| HK40068903A (en) | Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide | |
| WO2021014169A1 (en) | Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide | |
| EP4413976B1 (en) | A new vamorolone preparation exhibiting improved solubility | |
| EP4003977B1 (en) | Pyridine derivatives as calcium-activated chloride channel modulators | |
| EP3184516A1 (en) | Crystalline inclusion complexes of mirabegron with beta-cyclodextrin | |
| WO2025179296A1 (en) | Crystalline forms of nu-3 and uses thereof | |
| HK40109507A (en) | A new vamorolone preparation exhibiting improved solubility | |
| HK40109507B (en) | A new vamorolone preparation exhibiting improved solubility | |
| Di Lallo | Crystallization studies and identification of crystalline forms suitable for inhalation in drug discovery |